Beta-2 adrenergic receptor Agonists
42 drugsAbout Beta-2 adrenergic receptor
The beta 2-adrenoceptor (ADRB2) is a GPCR that mediates adrenaline and noradrenaline effects in the sympathetic nervous system, triggering smooth muscle relaxation.
ADRB2 is a validated drug target with strong genetic support (max score 0.90) linking it to skeletal system abnormalities. This genetic evidence, combined with clinical success, strengthens the rationale for targeting ADRB2.
Five FDA-approved drugs, including BREYNA, SYMBICORT, and SEREVENT, target ADRB2, all of which are small molecules. These drugs are used exclusively in respiratory therapeutic areas.
Beta-2 adrenergic receptor Genetic Evidence Strong
ADRB2 has strong genetic support linking it to skeletal system abnormalities (score 0.90).
Strong genetic support suggests a higher likelihood of clinical trial success for ADRB2-targeting drugs.
Evidence Across Diseases
1 totalGWAS and other genetic studies link ADRB2 to 1 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for ADRB2 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Beta-2 adrenergic receptor Drugs
Four companies, including Viatris and Boehringer Ingelheim, have approved ADRB2-targeting drugs.
The presence of established players may present entry barriers for new companies.
Beta-2 adrenergic receptor Drug Modality Landscape
Modalities
Routes of Administration
Beta-2 adrenergic receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Beta-2 adrenergic receptor Clinical Trials 1,220 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Beta-2 adrenergic receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 186 | 156 | 18 | 12 | 90% |
| Phase 2 | 286 | 217 | 37 | 32 | 85% |
| Phase 3 | 367 | 293 | 42 | 31 | 87% |
| Phase 4 | 381 | 279 | 55 | 47 | 84% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Beta-2 adrenergic receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Beta-2 adrenergic receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Beta-2 adrenergic receptor Drug Approval Timeline (1978 - 2023)
Supraventricular Tachycardia
Supraventricular Tachycardia
The first ADRB2-targeting drug was approved in 1994, with the most recent in 2022.
The continued approval of new drugs suggests ongoing innovation and market potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 22 companies competing
- • Market share by company
Full Drug Portfolio
- • All 42 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 42-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 478 (170 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Beta-2 adrenergic receptor. A trial counts if an approved drug acting on Beta-2 adrenergic receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.